Nasdaq Stockholm AB: Diagonal Bio AB receives observation status

Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation. 

The rules of Nasdaq First North Growth Market state that an issuer can be given
observation status if there is material adverse uncertainty in respect of the
issuer's financial position. 

With reference to the above, Nasdaq Stockholm AB decides that the shares in
Diagonal Bio AB (DIABIO, ISIN code SE0015961826, order book ID 227665) shall be
given observation status. 

For further information about this exchange notice please contact Enforcement &
Investigations, telephone [phone]. 



Nasdaq Stockholm AB